Testing for HER2 status is crucial for the diagnosis and treatment of certain cancers. The two primary methods for determining HER2 status are Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH). IHC measures the amount of HER2 protein on the surface of cancer cells, while FISH assesses the number of HER2 genes in the cancer cells. The results of these tests help guide treatment decisions.
